Elsewhere Biogen is in the early stages of launching three products. One Qalsody was approved in April for a small segment of ALS patients who have specific genetic mutations. Another Zurzuvae is a new postpartum depression drug that Biogen secured rights to through a multibilliondollar collaboration agreement with Sage Therapeutics